International research published in the Journal of the American College of Cardiology reveals that people who develop myocarditis after receiving an mRNA COVID-19 vaccine are less likely to die of the condition compared to those who develop the condition as a result of a viral infection.
The research team compared 104 people who were hospitalised for myocarditis within a month of their vaccine with 762 people who were diagnosed with the heart condition due to infection prior to the pandemic.
The researchers found that one person with vaccine-related myocarditis died (about 1% of the patients), while 11% of the infection-related myocarditis patients died.
The researchers concluded: “This study found a significantly lower rate of mortality among individuals with myocarditis after mRNA vaccination compared with those with viral infection-related myocarditis. The prognosis of this iatrogenic condition may be less severe than naturally acquired viral infection-related myocarditis.”
To read the research, visit: sciencedirect.com/science/article/abs/pii/S0735109722071078?via%3Dihub
